Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PFE would probably argue for "apportionment" if the case reached the stage of awarding damages, but it seems like a weak counter since ritonavir is not an active agent against COVID and it is only in the mix because of the pharmacokinetic deficiencies of nirmatrelvir.
Patent award apportionment (Ritonavir)
Should the inclusion of Ritonavir be expected to significantly reduce any potential infringement award due to apportionment?
Any thoughts?
Reversing nicely... Can't wait to see it over $15 in the coming weeks (hopefully)
SEC reported Today (11JAN2024) that MILLENNIUM MANAGEMENT LLC INCREASED $ENTA shares.
Before: 1,024,676 Shares.
Now: 1,314,949 Shares.
Newly Added: 290,273 Shares.
Increase: 28.33%
Approx Trxn Value :$3.19 M
Own %: 6.20%
#ThinkSabio #StockMarket #SEC #SEC-Update $ENTA: $11.31
— ThinkSabio.com (@think_sabio) January 11, 2024
Sector: Healthcare
SEC reported Today (11JAN2024) that MILLENNIUM MANAGEMENT LLC INCREASED $ENTA shares.
Before: 1,024,676 Shares.
Now: 1,314,949 Shares.
Newly Added: 290,273 Shares.
Increase: 28.33%
Approx Trxn Value… pic.twitter.com/ETn0mTTiBC
ENTA updated corporate slides (1/8/24):
https://ir.enanta.com/static-files/0b9a9564-339c-4501-8c98-eab636846bf4
Differences between the 1/8/24 slides and the previous version (9/12/23) are relatively minor. (In the bullet points below, I’ve omitted mention of slides that were merely re-sequenced with no changes to the content.)
• The pipeline chart on slide 5 includes the newly disclosed preclinical program in chronic spontaneous urticaria (CSU), an autoimmune disease.
• EDP-938, ENTA’s lead RSV compound, is now called Zelicapavir (slides 10-16).
• Old slides 18-20 on the hMPV program are gone; ENTA previously announced the termination of this program for business reasons.
• Slides 21-25 on the EDP-235 program supersede old slides 22-31; the new slides summarize the phase-2 data textually but omit the K-M curves that were previously displayed.
• Slides 27-28 on the HBV program supersede old slides 33-35, condensing this material.
• Slides 30-33 have info on the new CSU program.
• Slide 34 shows 2024 catalysts.
You mentioned TGTX options...its up over 20 per cent since you did.. If you bought call options..good for you
Could the Mgt surprise us with partnership news ? Enanta plans to pursue any future COVID-19 efforts in the context of a collaboration, including the development of EDP-235, an oral, once-daily, Phase-3-ready, 3CL protease inhibitor which has been granted Fast Track designation by the FDA.
Meanwhile.. I just added some FEB 12.50 calls on Friday for 1 dollar each
This is not the first time that Enanta has explored molecules for therapeutic use in immunology:
Cystic Fibrosis - macrolide 2005
Inflammatory bowel disease - macrolide 2008
Name your disease - cyclosporine adnauseam
Hopefully they have learned a lot and the new venture yields more economic rewards that the past ventures.
I thought I would be a long time holder, but getting out sooner is looking better to me all of the time.
Yesterday it takes 752,300 shares to move the price up.. today's early drop was based on mere 30k shares. Somehow is recycling the shares like no tomorrow. Cash + Royalty worth 20 bucks, We get paid 9 dollars for the assets.
laughing all the way to the bank..scenario..experiencing lol pretty good music to support the statement
I hope it goes to 20 in the next 2 weeks...then some of my 15 cents call options will become 10 dollars...lol...they're already over 2
Highly unlikely, IMO.
Is it likely that an agent from this program could be used to counter the itch associated with their MASLD candidates?
Just the net cash + 45% royalty alone translates to $20 per share for ENTA.
Its COVID drug is not dead as PFE's still make billions in sale.
Good to see ENTA over 11...didn't happen since October 1.... Now...as they say..SKY IS THE LIMIT....we will be having a breakout... and hopefully over 15 in couple of weeks
Interesting and I hope its good to the ear of the market....
ENTA’s new non-virology program is in immunology:
https://finance.yahoo.com/news/enanta-pharmaceuticals-updates-research-development-120000343.html
Thanks for the info...I am hoping that their early 2024 announcement is going to happen soon and it will be positive for the stock price.. That's my bet anyway.
The volume is not any greater than usual, and the short interest is quite deep. This stock often trades in the opposite direction of the Nasdaq indexes, especially when there is a move of more than 1% in the Nasdaq.
It probably isn't... since the volume is much higher already and we still have 2 more hours to go... Buyers have arrived back from vacation
Thanks..all true..and its moving....
ENTA is on the JPM schedule for Wed Jan 10 at 12:45pm ET.
They haven't made the announcement yet. while several other companies already did. If you're talking about 42nd Annual JPM healthcare conference.
https://www.bing.com/search?q=42nd%20Annual%20J.P.%20Morgan%20Healthcare%20Conference&FORM=ARPSEC&PC=ARPL&PTAG=30165
You can actually have 10 thousand open interest and everything can go to zero... Open interest is not really an indication for anything.. I currently own almost the half open interest and the lowest I paid was 15 cents and highest 45 cents... Stock price must go up for it to work..not open interest..not spread
..RVNC options price is more expensive for Jan 10 calls than ENTA even though ENTA stock price almost touched 10 today... And ENTA mgt will have something to say on early Jan. Much more fanfare in RVNC options market than ENTA
tax loss selling is over ..it seems
It should at minimum trade back to cash level given the remaining royalties worth about 200mm
It’s a double from here easily
Added more for 9.4... About to go higher sooon
Jan 10 investor conf could help the price to go up with any positive news
ALVR also has an RSV program.
ALVR106 is an allogeneic, off-the-shelf, multi-virus specific T-cell therapy candidate designed to target human metapneumovirus (hMPV), influenza, parainfluenza virus (PIV), and respiratory syncytial virus (RSV).
Recent setbacks in T-cell therapy, such as Atara Biosecience's failure in MS, raise questions about the field's overall effectiveness. This could potentially remove a competitor from the RSV space, making ALVR106 more attractive to larger pharmaceutical companies.
ALVR failed in Phase 3. How does it affect ENTA? I think one more less competition. Do we have a chance to do some deals with Gilead Sciences?
I know a lot of people that have received all of the COVID vaccines and recently had COVID. All of them, especially seniors, were dissatisfied that they did not receive a prescription. All of the cases that I have known of have resolved or are on the mend without complication, but I do not understand why ENTA's potential treatment is just sitting around when the reason for not prescribing the current SOC seems to be due to possible interactions with the meds that most seniors utilize daily. I mean, really - we saw an EUA for an antibody therapy against COVID, but nobody can do anything with ENTA's small molecule drug.
market does not actually think from time to time.
Otherwise, you won’t have name trading at 50x sales
When the challenge results for the first RSV antiviral were announced the stock quickly tanked and most of the publicity called the trial a failure. I agree that the market value is at all time lows, but I am cautious because selling ENTA for year end tax losses indicates that there is not much belief that any of those "free shots" are going to pan-out in the near future, i.e., there is a belief that there is plenty of time to make purchases of ENTA after first profiting form other near term purchases.
I bought on the positive news of the first RSV challenge study, I already had an accumulation of shares going back as far as 2015; I was baffled when all of the negative responses to the challenge study were vocalized.
That is my sad, sad story. I continue to have a lot of hope for Enanta, but my new expectations are that I have spent enough money, I am still faithful to my belief that the company is quite valuable far beyond my average cost, and I accept that any new investments for me are likely better spent on other equities which have demonstrated better trends in response to positive news.
Merry, Merry,
Sinking-and-Stinking-On-Positive-News
I have been buying
Not hard to add as it is trading so much below cash value with multiple free shots to much higher valuation.
"ENTA with a nice jump today on no news,"
And today it got hit - again with no news. Looks like tax selling is not over yet. Only 6 more trading days.
Interesting. Word is getting out.
https://twitter.com/factcatpoll/status/1736081974991741217
Thanks Dew and DC15 for the heads up and the link. EDP-323 is now up at bat with a study completion date in mid 2024. I assume we will hear about the new drug candidates ENTA is working on before that.
This is the trial listing:
https://clinicaltrials.gov/study/NCT06170242
Followers
|
98
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
3309
|
Created
|
03/20/13
|
Type
|
Free
|
Moderators DewDiligence |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |